Bupropion for the treatment of methamphetamine dependence in non-daily users: A randomized, double-blind, placebo-controlled trial. (1st May 2015)

• Record Type: Journal Article
• Authors: Anderson, Ann L.; Li, Shou-Hua; Markova, Denka; Holmes, Tyson H.; Chiang, Nora; Kahn, Roberta; Campbell, Jan; Dickerson, Daniel L.; Galloway, Gantt P.; Haning, William; Roache, John D.; Stock, Christopher; Elkashef, Ahmed M.
• Is Part Of: Drug and alcohol dependence. Volume 150(2015)
• Page Start: 170
• Page End: 174
• Publication Date: 2015-05-01
• Subjects: Bupropion -- Methamphetamine -- Substance-related disorders -- Drug therapy -- Medication adherence -- Patient acuity; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2015.01.036
• Languages: English
• ISSNs: 0376-8716

Abstract

Highlights: Bupropion SR 150 mg BID, vs. matched placebo, for 12 weeks to 204 treatment-seekers. 3× per week urines for meth and bupropion levels. No biomarker for placebo. No significant difference between treatment groups in % abstinent in Weeks 11–12. Bupropion adherence per protocol was achieved by just 47%. Additional data show wide range of adherence patterns, max levels, and clearance rates. Abstract: Aim: Bupropion was tested for efficacy to achieve methamphetamine (MA) abstinence in dependent, non-daily users. Methods: A randomized, double-blind, placebo-controlled trial, with 12-week treatment and 4-week follow-up, was conducted with 204 treatment-seeking participants having MA dependence per DSM-IV, who used MA on a less-than-daily basis. 104 were randomized to matched placebo and 100 to bupropion, sustained-release 150 mg, twice daily. Participants were seen three times weekly to obtain urine for MA and bupropion assays, study assessments, and thrice weekly, 90-min, group psychotherapy. There was no biomarker for placebo adherence. The primary outcome was achievement of abstinence throughout the last two weeks of treatment; 'success' requiring at least two urine samples during each of Weeks 11 and 12, and all samples MA-negative (<300 ng/mL). Results: Bupropion and placebo groups did not differ significantly in the percentage achieving abstinence for the last 2 weeks of treatment (chi-square, p = 0.32). Subgroup analysis of participants with lower baseline MA use (≤18 of last 30 days before consent) also revealed no difference in success between groups ( p = 0.73). Medication adherence per protocol (detectable bupropion, >5 ng/mL, in ≥50% of urine samples from Study Weeks 1–10 and ≥66% of urine samples from Weeks 11 to 12) was achieved by 47% of participants taking bupropion. Conclusions: These data indicate that bupropion did not increase abstinence in dependent participants who were using MA less-than-daily. Medication non-adherence was a limitation in this trial. Psychosocial therapy remains the mainstay of treatment for MA dependence. Further research on subgroups who may respond to bupropion may be warranted.